CR20220319A - MÉTODO PARA EL TRATAMIENTO DE CÁNCER UTILIZANDO CÉLULA ADYUVANTE ARTIFICIAL (aAVC) - Google Patents

MÉTODO PARA EL TRATAMIENTO DE CÁNCER UTILIZANDO CÉLULA ADYUVANTE ARTIFICIAL (aAVC)

Info

Publication number
CR20220319A
CR20220319A CR20220319A CR20220319A CR20220319A CR 20220319 A CR20220319 A CR 20220319A CR 20220319 A CR20220319 A CR 20220319A CR 20220319 A CR20220319 A CR 20220319A CR 20220319 A CR20220319 A CR 20220319A
Authority
CR
Costa Rica
Prior art keywords
aavc
treating cancer
cancer
vector cells
treating
Prior art date
Application number
CR20220319A
Other languages
English (en)
Inventor
Kanako Shimizu
Keisuke Ohsumi
Taku Yoshida
Masayuki KANKI
Shinichiro Fujii
Original Assignee
Riken
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken, Astellas Pharma Inc filed Critical Riken
Publication of CR20220319A publication Critical patent/CR20220319A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • User Interface Of Digital Computer (AREA)

Abstract

La presente invención encuentra escala apropiadas de la dosis de a-GalCer cargado en la superficie de la célula aAVC, así como la cantidad de a-GalCer cargado en la superficie de la célula aAVC, en una composición farmacéutica que contiene aAVC, las cuales se prefieren en términos de garantizar la efectividad y seguridad en el tratamiento y prevención de un cáncer utilizando aAVC; y proporciona un método efectivo y seguro para el tratamiento o prevención de un cáncer utilizando aAVC para el tratamiento efectivo y seguro de un cáncer; y una composición farmacéutica que comprende a la misma, etc.
CR20220319A 2019-12-02 2020-12-01 MÉTODO PARA EL TRATAMIENTO DE CÁNCER UTILIZANDO CÉLULA ADYUVANTE ARTIFICIAL (aAVC) CR20220319A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019217712 2019-12-02
PCT/JP2020/044587 WO2021112056A1 (ja) 2019-12-02 2020-12-01 人工アジュバント細胞（ａＡＶＣ）を用いたがんの治療方法

Publications (1)

Publication Number Publication Date
CR20220319A true CR20220319A (es) 2022-11-03

Family

ID=76222356

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220319A CR20220319A (es) 2019-12-02 2020-12-01 MÉTODO PARA EL TRATAMIENTO DE CÁNCER UTILIZANDO CÉLULA ADYUVANTE ARTIFICIAL (aAVC)

Country Status (20)

Country Link
US (2) US11617790B2 (es)
EP (1) EP4070810A4 (es)
JP (2) JP6912765B1 (es)
KR (1) KR20220119029A (es)
CN (1) CN114929272A (es)
AR (1) AR122341A1 (es)
AU (1) AU2020398783A1 (es)
BR (1) BR112022010750A2 (es)
CA (1) CA3162121A1 (es)
CL (1) CL2022001458A1 (es)
CO (1) CO2022008737A2 (es)
CR (1) CR20220319A (es)
DO (1) DOP2022000109A (es)
EC (1) ECSP22049665A (es)
IL (1) IL293483A (es)
JO (1) JOP20220122A1 (es)
MX (1) MX2022006712A (es)
PE (1) PE20221421A1 (es)
TW (1) TW202134265A (es)
WO (1) WO2021112056A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
ES2774707T3 (es) * 2006-02-22 2020-07-22 Riken Inmunoterapia mediante la utilización de células capaces de co-expresar un antígeno diana y CD1d y pulsadas con un ligando de CD1d

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
ES2774707T3 (es) 2006-02-22 2020-07-22 Riken Inmunoterapia mediante la utilización de células capaces de co-expresar un antígeno diana y CD1d y pulsadas con un ligando de CD1d
JP2007261876A (ja) 2006-03-28 2007-10-11 Tdk Corp 誘電体粒子、誘電体磁器組成物およびその製造方法
JPWO2010061930A1 (ja) 2008-11-28 2012-04-26 独立行政法人理化学研究所 ＣＤ１ｄ及び標的抗原の共発現アロ細胞を用いた免疫療法
KR101194265B1 (ko) 2008-12-01 2012-10-29 주식회사 한국인삼공사 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법
KR20130018778A (ko) 2010-03-25 2013-02-25 쓰리엠 이노베이티브 프로퍼티즈 컴파니 복합 층
US10316332B2 (en) * 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
EP2738253A4 (en) 2011-07-29 2015-04-22 Riken CELL FOR USE IN IMMUNOTHERAPY WITH A MODIFIED NUCLEIC ACIDIC CONSTRUCTIVE FOR WILMS TUMORGEN PRODUCT OR FRAGMENT THEREOF, METHOD FOR PRODUCING THIS CELL AND NUCLEIC ACIDIC CONCRETE SAID

Also Published As

Publication number Publication date
CL2022001458A1 (es) 2023-02-24
IL293483A (en) 2022-08-01
US11617790B2 (en) 2023-04-04
JOP20220122A1 (ar) 2023-01-30
CN114929272A (zh) 2022-08-19
AU2020398783A1 (en) 2022-06-09
US20220016239A1 (en) 2022-01-20
JPWO2021112056A1 (ja) 2021-12-02
EP4070810A1 (en) 2022-10-12
BR112022010750A2 (pt) 2022-08-16
EP4070810A4 (en) 2024-04-17
WO2021112056A1 (ja) 2021-06-10
MX2022006712A (es) 2022-09-12
US20230381305A1 (en) 2023-11-30
PE20221421A1 (es) 2022-09-20
CA3162121A1 (en) 2021-06-10
KR20220119029A (ko) 2022-08-26
DOP2022000109A (es) 2022-10-16
JP2021155443A (ja) 2021-10-07
CO2022008737A2 (es) 2022-08-09
ECSP22049665A (es) 2022-08-31
AR122341A1 (es) 2022-09-07
TW202134265A (zh) 2021-09-16
JP6912765B1 (ja) 2021-08-04

Similar Documents

Publication Publication Date Title
CR20220319A (es) MÉTODO PARA EL TRATAMIENTO DE CÁNCER UTILIZANDO CÉLULA ADYUVANTE ARTIFICIAL (aAVC)
PH12019502132A1 (en) Combination therapy for the treatment or prevention of tumours
MX2023007193A (es) Inhibidores de enpp1 y su uso para el tratamiento del cancer.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2019012884A (es) Terapia de combinacion.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
WO2018064588A3 (en) Tert immunogenic compositions and methods of treatment using the same
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
WO2020076760A3 (en) Sphingoid compounds for use in the prophylaxis and/or therapy of a viral infection
MX2024005228A (es) Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
MX2020011737A (es) Metodos de tratamiento con vitamina d.
MX2021008928A (es) Métodos para mejorar la protección contra lesiones vasculares y de organos, la recuperación hematopoyética y la supervivencia en respuesta a la radiacion corporal total/exposicion química.
MX2017000886A (es) Tratamiento con cis-clomifeno de sofocos y perdida osea inducidos por privacion de androgeno terapeutica.
EP4393548A3 (en) Formulations and treatments employing hydroxypyridonate actinide/lanthanide decorporation agents
WO2023164455A3 (en) Compositions and methods to modulate the immune system
MX2022000663A (es) Formulaciones farmaceuticas que contienen gaboxadol para tratamiento terapeutico.
WO2019241742A8 (en) Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
NZ771293A (en) Dosing regimens for treating hypoxia-associated tissue damage
MX2021005905A (es) Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
MO et al. Effects of different treatments of glyphosate on the urge corruption of Eucalyptus stumps
MX2019001210A (es) Composicion farmaceutica anticancer.